sector medic suppli devic
 lack recoveri suggest deeper issu
downgrad neutral
messag report disappoint result sale
yoy miss two quarter sluggish growth book
longer believ reason assign primari blame slowdown fda
rp letter rather think increasingli like impella enter flatter part
adopt curv effect transit mere exacerb rp disrupt
continu see signific long-term growth potenti impella experi
suggest process establish new normal growth trajectori
could protract one result downgrad neutral
follow second straight lacklust perform think increasingli like
wrestl structur challeng rather transient headwind
call may manag attribut subpar perform primarili
confus disrupt caus fda commun regard impella rp view
seem support abrupt slowdown compani experienc march
sign improv april rep chanc clear misconcept
rp post approv perform howev april momentum fade cours
manag revis guidanc impli much gradual recoveri
balanc year thursday call manag acknowledg impella
like move earli adopt earli major phase life cycl
transit introduc new challeng sale forc need overcom drive
growth includ need go deeper larg account spend time
smaller commun hospit impella penetr lowest today
alreadi begun take step facilit shift strategi believ could still sever
quarter success initi accur judg
importantli subscrib thesi impella approach peak
penetr estim still twice mani intra-aort balloon
pump use year impella pump believ clinic
evid gener date make solid case impella prefer method
establish hemodynam support vast major patient clinic
literatur without gap weak spot critic technolog push back
howev believ must continu demonstr impella valu win
reluct physician unfortun long anticip timelin complet
compani stemi trial mean best chanc new level evid may still
meantim key question level growth rate stabil
guidanc call revenu year meanwhil manag
point sale sequenti impli low double-digit growth
current quarter yet even recent pullback share still trade
revis ntm sale forecast level commensur top line trajectori
will assum growth would reacceler rp letter
primari culprit slowdown longer obviou us
case model call grow revenu compound-annual-growth-rate
vacuum would like view strong growth trajectori compani
size experi tell us process establish new normal
high growth name begin deceler often protract difficult one stock
downgrad neutral long view differenti med-tech
asset given combin growth profit lack direct competit
uniqu profil help support premium valuat stock compani
execut high level howev convinc remain case
work current challeng result view risk/reward level
rel balanc lower rate neutral buy
page analyst certif import disclosur
leader mechan circulatori support dedic enabl safer
treatment high-risk patient cardiovascular diseas recov injur heart
muscl estim patient receiv one compani famili impella
heart pump last year yet believ scratch surfac impella
long-term potenti estim market opportun includ
impella smallest heart pump world design provid temporari
hemodynam support patient undergo high-risk procedur whose cardiac
function compromis sinc impella first receiv approv
impella famili pump use support ten thousand peopl
abiom revenu grow compound-annual-growth-rate period howev second straight
quarter disappoint us impella growth us question manag prior
assert recent weak caus fda commun regard proper
use impella rp pump instead think increasingli like busi
transit earli adopt phase flatter part penetr curv
fda letter mere exacerb structur issu believ manag
take right step drive deeper penetr chang take time
share trade ntm revenu estim high end
multipl rang high-growth peer smid-cap med-tech group believ
stock remain valu compani abl sustain top line growth
repres high end manag guidanc rang stock like
penalti box compani demonstr improv momentum
near-term catalyst outsid quarterli earn report horizon see better
opportun elsewher downgrad share buy neutral
upsid risk rate includ potenti impella adopt exceed street
expect pipelin advanc improv long-term outlook failur
competit materi potenti larg player bring portfolio
downsid risk rate includ potenti impella adopt fall short
street forecast pipelin setback clinic failur weaken abiom long-term
outlook faster-than-expect progress potenti impella competitor
premium valuat leav littl margin error view
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
million usd
servic
revenu geographi
 unit
 unit indic
compani report guggenheim secur llc estim
page analyst certif import disclosur
